Stents and other devices having extracellular matrix coating
View Patent ↗Provided herein are devices comprising a stent; and a coating on said stent comprising a polymer and an active agent, wherein the active agent comprises at least one of: extracellular matrix and an extracellular matrix component. Provided herein are methods of preparing a device comprising a stent and a coating on said stent; said method comprising: providing a stent; and forming a plurality of layers on said stent; wherein the coating comprises a polymer and at least one of said layers comprises one or more active agents; wherein at least a portion of the active agent comprises at least one of extracellular matrix and an extracellular matrix component.
1. A device comprising
a substrate; and
a coating on said substrate comprising a first polymer and an active agent, wherein the active agent comprises a macrolide immunosuppressive drug in crystalline form and an extracellular matrix, wherein the extracellular matrix comprises an interlocking mesh of fibrous proteins and glycosaminoglycans (GAGs).
2. The device of claim 1 , wherein the extracellular matrix comprises an extracellular matrix component comprising at least one of: heparin sulfate, choindroitin sulfate, keratan sulfate, hayaluronic acid, collagen, elastin, fibronectin, laminin, merosin, tenascin, vitronectin, and fibrillin.
3. The device of claim 1 , wherein the substrate is at least one of a stent, an angioplasty balloon and a cutting balloon.
4. The device of claim 1 , wherein the first polymer is at least one of: a bioabsorbable polymer and a durable polymer.
5. The device of claim 1 , wherein substantially all of the active agent remains within said coating and on said substrate until the implantable device is deployed at an intervention site inside the body of a subject, wherein upon deployment of said device in the body of said subject a portion of the active agent is delivered at said intervention site along with at least a portion of said polymer, and wherein the device is adapted to be delivered to a body lumen.
6. The device of claim 1 , wherein active agent particles are sequestered or encapsulated within a microstructure.
7. The device of claim 1 , wherein the coating is formed on said substrate through a process comprising depositing said polymer active agent by an e-RESS, an e-SEDS, or an e-DPC process.
8. The device of claim 1 , wherein the coating comprises a plurality of layers a first layer comprises the first polymer, a second layer comprises the active agent, a third layer comprises a second polymer, a fourth layer comprises the active agent, and a fifth layer comprises a third polymer.
9. The device of claim 8 , wherein at least two of said first polymer, said second polymer and said third polymer are the same polymer.
10. A stent delivery system comprising:
an elongate member having an inflation lumen and a guidewire lumen therein;
a balloon having an interior that is in fluid communication with the inflation lumen; and
a coated stent mounted on the balloon, wherein the coated stent comprises a stent and a plurality of layers that form a coating on said stent;
wherein at least one of said layers comprises a polymer and at least one of said layers comprises an active agent, wherein the active agent comprises a macrolide immunosuppressive drug in crystalline form and an extracellular matrix, wherein the extracellular matrix comprises an interlocking mesh of fibrous proteins and glycosaminoglycans (GAGs).
11. A bioabsorbable device comprising
a bioabsorbable substrate comprising a first active agent; and
a coating on said substrate wherein the coating comprises a first polymer,
wherein the first active agent comprises a macrolide immunosuppressive drug in crystalline form and an extracellular matrix, wherein the extracellular matrix comprises an interlocking mesh of fibrous proteins and glycosaminoglycans (GAGs).
12. A bioabsorbable device comprising
a bioabsorbable substrate; and
a coating on said substrate wherein the coating comprises a first polymer, a first active agent and a second active agent, wherein the first active agent comprises extracellular matrix, the extracellular matrix comprises an interlocking mesh of fibrous proteins and glycosaminoglycans (GAGs), and the second active agent comprises a macrolide immunosuppressive drug in crystalline form.
13. The device of one of claims 11 and 12 , wherein the bioabsorbable substrate comprises at least one of a bioabsorbable metal framework and a second polymer, wherein the second polymer is bioabsorbable.
14. The device of one of claims 11 and 12 , wherein the first polymer degrades by at least one of bulk erosion and surface erosion.
15. The device of one of claims 11 and 12 , wherein the device is delivered to a target tissue and returns endothelial function to the target tissue at 28 days from device delivery.